Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

DSpace Repository

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Author: Heitmann, Jonas S.; Schlenk, Richard F.; Doerfel, Daniela; Kayser, Sabine; Doehner, Konstanze; Heuser, Michael; Thol, Felicitas; Kapp-Schwoerer, Silke; Labrenz, Jannik; Edelmann, Dominic; Maerklin, Melanie; Vogel, Wichard; Bethge, Wolfgang; Walz, Juliane S.; Grosse-Hovest, Ludger; Steiner, Martin; Jung, Gundram; Salih, Helmut R.
Tübinger Autor(en):
Heitmann, Jonas S.
Dörfel, Daniela
Märklin, Melanie
Walz, Juliane S.
Salih, Helmut R.
Jung, Gundram
Steiner, Martin
Grosse-Hovest, Ludger
Bethge, Wolfgang Andreas
Vogel, Wichard
Published in: Journal of Hematology & Oncology (2023), Bd. 16, H. 1
Verlagsangabe: London : Bmc
Language: English
Full text: http://dx.doi.org/10.1186/s13045-023-01490-w
ISSN: 1756-8722
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)